BlossomHill Therapeutics, Inc. (BLSM) vs Nuvectis Pharma, Inc. (NVCT)

A side-by-side comparison of BlossomHill Therapeutics, Inc. and Nuvectis Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
BlossomHill Therapeutics, Inc. logo
BLSM
BlossomHill Therapeutics, Inc.
$503M
$17.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Nuvectis Pharma, Inc. logo
NVCT
Nuvectis Pharma, Inc.
$532M
$20.03HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BLSM vs NVCT

growth of $100 · dividends reinvested · last 1y
BLSM +24.6% (+24.6%/yr)NVCT +13.6% (+13.6%/yr)BLSM compounded faster over this window
100120140160Start $100$125$114
BLSM NVCT

BLSM vs NVCT: by the numbers

  • •NVCT is the larger company ($532M vs $503M market cap).

Metrics side by side

Valuation

MetricBLSMNVCT
P/B ratioN/A58.53

Profitability

MetricBLSMNVCT
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROEN/A-306.61%
ROIC-43.41%-317.86%

Go deeper

Full BLSM analysisFull NVCT analysisInteractive comparison tool

Dig into the metrics

BlossomHill Therapeutics ROENuvectis Pharma ROEBlossomHill Therapeutics operating marginNuvectis Pharma operating marginBlossomHill Therapeutics revenue growthNuvectis Pharma revenue growthBlossomHill Therapeutics free cash flowNuvectis Pharma free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.